


## EGFR/ErbB-2/ErbB-4 inhibitor-2

Cat. No.:	HY-112420
CAS No.:	179248-61-4
Molecular Formula:	C <sub>23</sub> H <sub>21</sub> N <sub>3</sub> O <sub>3</sub>
Molecular Weight:	387.43
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 33.33 mg/mL (86.03 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	2.5811 mL	12.9056 mL	25.8111 mL
		5 mM	0.5162 mL	2.5811 mL	5.1622 mL
	10 mM	0.2581 mL	1.2906 mL	2.5811 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.45 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	EGFR/ErbB-2/ErbB-4 inhibitor-2 (Compound 5) is a EGFR and ErbB inhibitor with IC <sub>50</sub> s of 0.017 μM, 0.08 μM, 1.91 μM <sup>[1]</sup> .		
IC <sub>50</sub> & Target	EGFR 0.017 μM (IC <sub>50</sub> )	ErbB2 0.08 μM (IC <sub>50</sub> )	ErbB4 1.91 μM (IC <sub>50</sub> )
In Vitro	EGFR/ErbB-2/ErbB-4 inhibitor-2 (Compound 5) also inhibits c-Src, VEGFR2, c-Fms and with IC <sub>50</sub> s of 0.30, 2.2, and 14.0 μM, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

### REFERENCES

[1]. Perry S Brignola, et al. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA